The Two-Way Route between Delirium Disorder and Dementia: Insights from COVID-19.

Acute encephalopathy COVID-19 Delirium Dementia Neurodegeneration Neurovascular unit SARS-CoV-2

Journal

Neuro-degenerative diseases
ISSN: 1660-2862
Titre abrégé: Neurodegener Dis
Pays: Switzerland
ID NLM: 101189034

Informations de publication

Date de publication:
2022
Historique:
received: 30 11 2022
accepted: 23 03 2023
medline: 14 4 2023
pubmed: 14 4 2023
entrez: 13 4 2023
Statut: ppublish

Résumé

Delirium disorder is a frequent neurological complication of SARS-CoV-2 infection and associated with increased disease severity and mortality. Cognitive impairment is a major risk factor for developing delirium disorder during COVID-19, which, in turn, increases the risk of subsequent neurological complications and cognitive decline. The bidirectional connection between delirium disorder and dementia likely resides at multiple levels, and its pathophysiological mechanisms during COVID-19 include endothelial damage, blood-brain barrier dysfunction, and local inflammation, with activation of microglia and astrocytes. Here, we describe the putative pathogenic pathways underlying delirium disorder during COVID-19 and highlight how they cross with the ones leading to neurodegenerative dementia. The analysis of the two-sided link can offer useful insights for confronting with long-term neurological consequences of COVID-19 and framing future prevention and early treatment strategies.

Sections du résumé

BACKGROUND BACKGROUND
Delirium disorder is a frequent neurological complication of SARS-CoV-2 infection and associated with increased disease severity and mortality. Cognitive impairment is a major risk factor for developing delirium disorder during COVID-19, which, in turn, increases the risk of subsequent neurological complications and cognitive decline.
SUMMARY CONCLUSIONS
The bidirectional connection between delirium disorder and dementia likely resides at multiple levels, and its pathophysiological mechanisms during COVID-19 include endothelial damage, blood-brain barrier dysfunction, and local inflammation, with activation of microglia and astrocytes. Here, we describe the putative pathogenic pathways underlying delirium disorder during COVID-19 and highlight how they cross with the ones leading to neurodegenerative dementia.
KEY MESSAGES CONCLUSIONS
The analysis of the two-sided link can offer useful insights for confronting with long-term neurological consequences of COVID-19 and framing future prevention and early treatment strategies.

Identifiants

DOI: 10.1159/000530566 PMID: 37054684
pubmed: 37054684
pii: 000530566
doi: 10.1159/000530566
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

91-103

Informations de copyright

© 2023 The Author(s). Published by S. Karger AG, Basel.

Auteurs

Giulia Bommarito (G)

Department of Clinical Neurosciences, Lausanne University Hospitals and University of Lausanne, Lausanne, Switzerland.

Valentina Garibotto (V)

Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals and NIMTlab, University of Geneva, Geneva, Switzerland.

Giovanni B Frisoni (GB)

Memory Center and LANVIE-Laboratory of Neuroimaging of Aging, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

Frédéric Assal (F)

Department of Clinical Neurosciences, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

Patrice H Lalive (PH)

Department of Clinical Neurosciences, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland.

Gilles Allali (G)

Department of Clinical Neurosciences, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Division of Cognitive and Motor Aging, Department of Neurology, Albert Einstein College of Medicine, Yeshiva University, Bronx, New York, USA.
Leenaards Memory Center, Lausanne University Hospitals and University of Lausanne, Lausanne, Switzerland.

Classifications MeSH